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Summary
Recent epidemiologic data suggest that sickle cell trait (HbAS; AS) is a risk factor for venous 
thromboembolism. We conducted an exploratory study of healthy subjects with AS under baseline 
conditions to determine whether a chronic basal hyperactivation of coagulation exists, and if so, 
what mechanism(s) contribute to this state. Eighteen healthy AS individuals were compared to 22 
African-American controls with a normal haemoglobin profile (HbAA; AA) and 17 patients with 
sickle cell disease (HbSS; SS). Plasma thrombin-antithrombin complexes and D-dimer levels were 
elevated in AS relative to AA patients (P = 0.0385 and P = 0.017, respectively), and as expected, 
were much higher in SS versus AA (P < 0.0001 for both). Thrombin generation in platelet poor 
plasma was indistinguishable between AA and AS subjects, whereas a paradoxical decrease in 
endogenous thrombin potential was observed in SS (P ≤ 0.0001). Whole blood tissue factor was 
elevated in SS compared to AA (P = 0.005), but did not differ between AA and AS. Plasma 
microparticle tissue factor activity was non-significantly elevated in AS (P = 0.051), but was 
clearly elevated in SS patients (P = 0.004) when compared to AA controls. Further studies in 
larger cohorts of subjects with sickle cell trait are needed to confirm the results of this preliminary 
investigation.
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As many as 200 million people worldwide are heterozygous carriers of a mutation in the 
HBB gene (HBB E6V, also termed HbS mutation or ‘sickle gene’), resulting in a condition 
known as sickle cell trait (HbAS, hereafter termed AS) (Piel et al, 2013) (Dr. S. Grosse, 
personal communication, US Centers for Disease Control and Prevention, Atlanta, GA). 
Although traditionally viewed as a benign carrier state, AS may be a risk factor for certain 
adverse outcomes, including venous thromboembolism (VTE) (Tsaras et al, 2009; Key & 
Derebail, 2010; Key et al, 2015). In a large case–control study of VTE in African-American 
subjects, we reported that AS was associated with an increased risk of VTE, with an odds 
ratio (OR) of about 2; more strikingly, AS appeared to confer a particularly high risk for 
pulmonary embolism (PE) (OR ≈ 4) (Austin et al, 2007). In addition, a possible interaction 
between AS and hormonal contraceptive usage may further heighten the risk of VTE in 
women of reproductive age (Austin et al, 2009). Other studies have also reported an 
association between AS and risk of VTE, particularly PE (Heller et al, 1979; Bucknor et al, 
2014; Folsom et al, 2015). This association was deemed a high priority area for further 
research in a recent National Institutes of Health conference on sickle cell trait (Goldsmith et 
al, 2012).
It has previously been reported that plasma levels of the ‘pre-thrombotic’ biomarkers 
thrombin-antithrombin complexes (TAT), prothrombin fragments 1 + 2 and D-dimers are 
elevated in subjects with AS compared to race-matched controls (Westerman et al, 2002). 
One additional study demonstrated elevated TAT complex levels in AS compared to non 
race-matched controls (Helley et al, 1997). However, comparison with race-matched 
controls is essential as both pre-thrombotic markers, such as D-dimer (Lutsey et al, 2006), 
and plasma thrombin generation (Roberts et al, 2013) are higher in healthy individuals of 
African descent.
In the present report, we sought to confirm the presence of a pre-thrombotic state in healthy 
subjects with AS using plasma markers of coagulation activation. Simultaneously, we 
investigated possible mechanisms that might account for the hypercoagulable state in AS 
subjects compared to healthy HbAA (AA) controls, as well as subjects with sickle cell 
disease (SCD; HbSS; SS), in whom a complex and multi-causal state of activation of 
coagulation has been well described (Ataga & Key, 2007; Lim et al, 2013). The choice of 
analytes was influenced by these prior studies, which have focused on both the trigger for 
coagulation activation in SS, such as circulating tissue factor (TF, also termed coagulation 
Factor III) (Key et al, 1998; Colella et al, 2012; Setty et al, 2012), as well as ‘downstream’ 
enhancement of thrombin generation capacity (Hemker et al, 2006; Gerotziafas et al, 2012; 
Lim et al, 2013; Noubouossie et al, 2013).
Methods
Study subjects
This exploratory cohort study was conducted at the University of North Carolina at Chapel 
Hill. Institutional Review Board approval was obtained and written informed consent was 
obtained from all study participants. The study included only African-Americans between 
the ages of 18 and 65 years. Ethnicity/race was self-declared.
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Subjects were recruited into three study categories: Group 1 or controls (AA) included 
subjects without any haemoglobinopathy; Group 2 included subjects with sickle cell trait 
(AS); and Group 3 included subjects with SCD (SS) with either HbSS or HbS-βthal0 
genotype. Exclusion criteria included the presence of a prior history of VTE, current 
pregnancy or use of hormonal contraceptive therapy and current use of anticoagulants or 
anti-platelet agents (the latter within the past 7 days). Subjects with SCD were also excluded 
if they had experienced a recent (<4 weeks) pain crisis or and/or hospitalization, had 
recently (<3 months) undergone surgery, or if they had received blood transfusion within the 
last 3 months. No subject in any group had diabetes mellitus or hypertension, cancer or an 
acute or chronic inflammatory disorder.
Phlebotomy and plasma preparation
After discarding the first 3 ml of blood, blood was drawn into appropriate commercial 
vacutainer or pre-prepared tubes and rapidly mixed. Samples obtained from a less than fully 
satisfactory venipuncture were discarded. For D-dimer and TAT analysis, blood was drawn 
into 3.2% sodium citrate. For thrombin generation and clot formation analyses, blood was 
drawn into 3.2% sodium citrate/18.5 μg/ml corn trypsin inhibitor to prevent contact 
activation (Luddington & Baglin, 2004). In each case, platelet-free plasma was prepared by 
centrifugation, followed by a second centrifugation step at 13 000 g for 2 min. Plasma 
aliquots were stored at −80°C until batched analysis could be performed. Frozen plasma 
samples were thawed rapidly at 37°C immediately prior to assay and discarded after use.
Materials
Factor VIIa and factor X were from Enzyme Research Laboratories, Inc. (South Bend, IN, 
USA). Chromogenic substrate Pefachrome FXa 8595 was from Centerchem, Inc. (Norwalk, 
CT, USA). Re-lipidated recombinant human TF (Innovin®) was from Siemens Healthcare 
Diagnostics Products GmbH (Marburg, Germany). Immunbind TF enzyme-linked 
immunosorbent assay (ELISA) kits were from American Diagnostica, Inc (Stamford, CT, 
USA). An inhibitory monoclonal antibody (HTF1) to TF was a kind gift from Ronald Bach, 
PhD (Minneapolis VA Medical Center, Minneapolis, MN, USA). Corn trypsin inhibitor was 
from Hematologic Technologies, Inc. (Essex Junction, VT, USA). Unilamiellar 
phospholipid vesicles [15% phosphatidylserine (PS), 41% phosphatidylcholine (PC) 41% 
and phosphatidylethanolamine (PE) 44%] were prepared as described (Hope et al, 1985).
Haematology profile
Routine haematological assays were performed using standard methods at the McClendon 
Clinical Laboratories at the University of North Carolina Memorial Hospital. Because the 
laboratory reports markedly low or undetectable serum haptoglobin values as ‘<220 mg/l’, 
this parameter was treated as a categorical variable, and observed values were divided into 
those that were below (<220 mg/l), within (220–1390 mg/l) and above (>1390 mg/l) the 
laboratory’s quoted normal reference range.
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Plasma D-dimer and thrombin-antithrombin (TAT) complexes
D-dimer on plasma samples was measured in the clinical laboratory using the HemosIL® D-
Dimer HS immuno-turbidic assay on an ACL TOP® coagulation analyser (Instrumentation 
Laboratory, Bedford, MA, USA) (Salvagno et al, 2008). Because the laboratory reports 
markedly low D-dimer values as ‘<150 μg/ml’, plasma D-dimer values were treated as a 
categorical variable, dividing observed values into those that were below (<150 μg/ml), 
within (150–229 μg/ml) and above (>229 μg/ml) the laboratory’s quoted normal reference 
range. Plasma TAT levels were determined by using an ELISA assay kit from Affinity 
Biologicals (Lancaster, ON, Canada).
Thrombin generation and fibrin formation in plasma
Thrombin generation was measured fluorometrically using Calibrated Automated 
Thrombography (CAT), as previously described (Machlus et al, 2009), using the TF and 
phospholipid reagents (final concentration, 1 pmol/l and 4 μmol/l, respectively) supplied by 
the manufacturer (Thrombinoscope BV, Maastricht, Netherlands). Parameters of interest 
included: (i) lag time; (ii) time to peak thrombin generation; (iii) peak thrombin level; and 
(iv) area under the curve [‘endogenous thrombin potential’ (ETP)].
Fibrin formation was measured turbidimetrically by continuous measurement of absorbance 
at 405 nm in a Spectramax microplate reader (Molecular Devices, Sunnyvale, CA, USA). 
Here, platelet-free plasma samples were re-calcified, and clotting was initiated by addition 
of Innovin® (1:60 000 dilution, final) and phospholipid vesicles (125 μmol/l, final), as 
previously described (Gray et al, 2011). Endpoints of interest included: (i) onset of fibrin 
formation; (ii) rate of fibrin formation; and (iii) absolute change in turbidity from baseline.
Microparticle tissue factor activity
As previously described (Key & Mackman, 2010), microparticles (MPs) were isolated from 
citrate anticoagulated platelet-free plasma by centrifugation at 20 000 g for 30 min. The 
pellet was re-suspended in HBSA (20 mmol/l HEPES, pH 7.4, 150 mmol/l NaCl, and 1 
mg/ml bovine serum albumin) and re-centrifuged at 20 000 g for 30 min, before final re-
suspension in 250 μl HBSA. MPs were incubated with factor VIIa (100 pmol/l, final) and 
factor X (135 nmol/l, final), in the presence of calcium (5 mmol/l, final) and anti-TF 
antibody (HTF1, 10 μg/ml final) or IgG control. Factor Xa generation was measured in 
aliquots by chromogenic substrate cleavage as described. Specific TF activity (fmol/l) was 
determined by subtracting the rate of factor Xa generated in the presence of HTF1 from the 
rate of factor Xa generated in the presence of IgG controls with reference to a standard curve 
generated using lipidated recombinant human TF (In-novin®). Effective TF concentration in 
each lot of Innovin® was calculated as previously described (Johnson et al, 2009).
Whole blood tissue factor activity
As previously described (Key et al, 1998), frozen whole blood samples were thawed at 37°C 
for 3 min, after which 250 μl was added to 900 μl TBS-EDTA (20 mmol/l Tris-HCl, pH 7.5, 
150 mmol/l NaCl, 100 mmol/l EDTA) and mixed by vortexing. Following three freeze-thaw 
cycles, sample pellets were prepared by high-speed centrifugation (100 000 g at 4°C for 60 
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min) and washed three times in TBS-EDTA before final suspension of the pellet in 250 μl 
HBSA. One hundred microlitre was incubated with HTF1 (4 μg/ml) or control antibody for 
60 min. Forty microlitre of each sample was then added to a 96-well plate in duplicate. Forty 
microlitre of factor mix (2 nmol/l factor VIIa and 300 nmol/l factor X in HBSA with 5 
mmol/l calcium) was then added to each well. Plates were incubated at 37°C for 2 h before 
adding 10 μl of EDTA. Forty microlitre of the chromogenic substrate, Pefachrome FXa 8595 
(final concentration 0.3 mmol/l) was added to each well. The rate of factor Xa cleavage of 
the chromogenic substrate at room temperature in each well was monitored in a 
ThermoMax® plate reader (Molecular Devices, Sunnyvale, CA, USA). Innovin® at various 
concentrations was used as the TF standard. TF-dependent procoagulant activity (pmol/l) 
was defined as the difference between the rates of factor Xa cleavage of substrate in the 
absence/presence of HTF1.
Inflammatory markers and cytokines
Cytokine and chemokine levels in citrated plasma were determined by colourimetric bead 
assay using the Luminex system and human-specific bead sets (R&D Systems, Minneapolis, 
MN, USA). Results were interpolated from 5-parameter-fit standard curves generated using 
the relevant recombinant human proteins (R&D Systems).
Statistical analysis
The primary goal of the study was to explore differences in coagulation and inflammatory 
parameters between subjects with AS and matched controls (AA). Patients with SS were 
included as a positive control and to examine whether any gene dosing effects were evident. 
The study had planned to enrol 20 subjects from each subtype (AA, AS and SS). As this was 
an exploratory study, sample size was estimated from prior studies that used similar assays 
in individuals with SS disease (Westerman et al, 2002; Ataga et al, 2008).
Descriptive analyses were performed to explore the distribution of each variable or analyte. 
Data for continuous variables were expressed as median values with interquartile ranges 
(IQR), and compared between groups (AA vs. AS and AA vs. SS) using the Mann–Whitney 
U test. For categorical data (D-dimers and haptoglobin), groups were compared using 
Fisher’s exact test. Spearman rank correlation was used to determine correlation between 
variables; in the case of a categorical variable (such as D-dimers), a rank of 1 was given to 
values falling below the reference range, a rank of 2 to values within the range, and a rank of 
3 to values above the quoted reference range. Significance was established at the 0.05 level; 
no adjustments were made for multiple comparisons, because this was an exploratory study.
Results
Study subject characteristics
Fifty-seven African-American subjects were recruited: 22 AA, 18 AS and 17 SS. Age was 
comparable amongst the groups with median ages of 37.5 (IQR: 32–45), 38.5 (IQR: 33–45) 
and 41 (IQR: 24.5–47.5) years for AA, AS, and SS, respectively. Ninety-one per cent of the 
AA controls were females, while females accounted for 56% of the AS subjects and 53% of 
the SS subjects.
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As expected, haemoglobin levels were similar for AA and AS subjects, but were 
substantially lower among those with SS, in whom anaemia was accompanied by evidence 
of accelerated haemolysis – specifically, higher serum lactate dehydrogenase (LDH) and 
lower haptoglobin values (Table I). Reticulocyte counts were not obtained. There was a 
trend towards lower serum haptoglobin and, to a lesser extent, higher serum LDH values in 
AS compared to control subjects. Total white blood cell counts were also higher in the SS 
group; this was accounted for by an increase in both absolute neutrophil and absolute 
monocyte counts. There was a trend towards elevated absolute monocyte counts in AS 
subjects. Platelet counts were higher in the SS group, but it is noteworthy that they were also 
marginally higher (P = 0.0474) in AS subjects (median: 325 × 109/l; IQR: 290–364 × 109/l) 
compared to AA controls (median: 285 × 109/l, IQR: 255–327 × 109/l).
Coagulation is activated in vivo in both SS and AS
D-dimer levels were elevated in every patient with SS, with a highly significant increase 
compared to controls (P < 0.0001) (Table II). However, D-dimer levels were also elevated in 
AS relative to AA (P = 0.017). It should be noted that D-dimers were above the laboratory’s 
reference range in 5 of 22 (23%) subjects in the AA control group. This probably reflects the 
fact that D-dimer levels are elevated in African-Americans compared to white Americans 
(Lutsey et al, 2006), who comprise the large majority of healthy subjects from whom the 
reference ranges are derived in the clinical laboratory.
Plasma TAT complexes showed similar results, with a marked increase in SS (P < 0.0001) 
and a more modest but significant increase in AS (P = 0.0385) (Table II). Notably, in the 
case of both the AS and SS groups, the distribution of values included a substantial number 
of subjects whose TAT levels overlapped with AA controls, and the overall differences 
between the groups and controls was driven by the population of outliers (data not shown). 
For the entire group of study subjects, TAT complexes and D-dimers were moderately well 
correlated, with a Spearman correlation coefficient of 0.55 (P < 0.0001).
Thrombin generation capacity and fibrin formation in AS or SS plasma are not increased
We next examined whether the capacity for thrombin generation is increased in the plasma 
of AS and SS subjects ex vivo, as elevated plasma TAT complexes point to the presence of 
accelerated thrombin generation in vivo. By CAT assay, neither lag time nor peak thrombin 
generation differed between the three groups (Table III). However, time to peak thrombin 
generation was shorter in SS vs. AA (P = 0.0001) (Fig 1). Unexpectedly, ETP was lower in 
patients with SS vs. AA (P ≤ 0.0001). Subjects with AA and AS did not differ in any CAT 
parameter.
Fibrin formation in plasma was also measured using a turbidimetric assay. The onset of 
fibrin formation was more rapid in SS compared to AA (P = 0.0418), although the 
subsequent rate of fibrin formation did not differ (Fig 2, Table III). The more rapid onset of 
fibrin formation in SS is consistent with the shorter time to peak thrombin generation in the 
CAT assay (Fig 1). Neither the rate, nor the change in turbidity (an indicator of fibrin 
network structure) differed significantly between AA and SS individuals. No changes were 
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noted in any of the measured parameters when AA and AS subjects were compared, also 
consistent with the thrombin generation assay data.
Microparticle TF procoagulant activity in AS
As described in Methods, circulating TF activity was measured using two separate assays – 
one for TF procoagulant activity in whole blood (WB-TF), and one for MP-associated TF 
(MP-TF) activity in cell free plasma. As previously reported (Key et al, 1998), WB-TF 
activity was elevated in SS disease compared to AA controls (P = 0.005). However, WB-TF 
did not differ between AA and AS subjects (P = 0.734) (Fig 3A). MP-TF procoagulant 
activity showed a trend towards being elevated in AS subjects (P = 0.051), and was clearly 
increased in SS subjects (P = 0.004) compared to controls (Fig 3B).
MP-TF activity levels and TAT complexes were only weakly correlated for the entire group 
(AA, AS and SS), with a coefficient of 0.30 (P = 0.0295). In addition, the correlation 
between MP-TF and D-dimers was only 0.28 (P = 0.0381), but this may have been 
influenced by the fact that D-dimer was treated as a categorical variable with only three 
levels. WB-TF did not correlate with TAT or D-dimer as evidenced by coefficients of 0.01 
(P = 0.9215) and 0.16 (P = 0.2442), respectively.
Inflammatory markers and cytokine levels are not elevated in AS
Several markers, including soluble CD40 ligand (P = 0.0276), tumour necrosis factor (TNF 
α; (P = 0.0003) and soluble vascular cell adhesion molecule 1 (VCAM1; P < 0.0001) were 
elevated in SS compared to AA controls, whereas epithelial-derived neutrophil-activating 
peptide 78 [ENA78 (CXCL5); P = 0.0276] and granulocyte colony-stimulating factor (P = 
0.0304) were significantly reduced (Table S1). C-reactive protein, an acute phase response 
marker that has been reported to be elevated in SS patients (Singhal et al, 1993), was not 
increased in this cohort. The inflammatory markers C-reactive protein, TNF α, interleukin 
(IL) 1-α, IL1β, IL6, and IL8 also did not differ between AA and AS subjects. Soluble P-
selectin levels trended higher in both AS (P = 0.0551) and SS (P = 0.0577) subjects, but 
without an apparent ‘gene dosing effect’ observed in these groups.
Discussion
Elevated levels of plasma D-dimers, and to a lesser extent, TAT complexes in this study are 
consistent with a previous report that coagulation is more activated in healthy subjects with 
AS compared to race-matched controls (Westerman et al, 2002). However, further larger 
scale studies will be required to definitely establish this association. We also included a 
cohort of patients with SS, and observed the expected pronounced elevation in the pre-
thrombotic markers in plasma (TAT complexes and D-dimers) compared to controls. 
Whether or not activation of coagulation in SS patients contributes to vaso-occlusive 
complications, such as pain crisis, stroke, or pulmonary hypertension remains an open 
question (Hillery & Panepinto, 2004; Ataga & Key, 2007; Pakbaz & Wun, 2014), but 
several pieces of evidence now support the conclusion that the risk of VTE is increased not 
only in SCD (Stein et al, 2006; Novelli et al, 2012; Naik et al, 2014), but also in sickle trait 
(Austin et al, 2007; Bucknor et al, 2014; Folsom et al, 2015). We examined whether 
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thrombin-generating capacity in AS and SS plasma is increased in parallel with the 
increased levels of circulating TAT and D-dimers. Paradoxically, ETP was reduced in 
individuals with SS (Fig 1). Several groups have addressed the question whether thrombin 
generation in plasma is elevated in SCD, with mixed and sometimes opposite conclusions 
(Lim et al, 2013). Notably, an analogous discrepancy between elevated TAT and/or D-dimer 
in vivo and normal or decreased ETP ex vivo has been described elsewhere, for example in 
normal pregnancy (Eichinger et al, 1999). When performed in cell-free plasma, ETP is 
dependent on the net balance between levels of procoagulant and anticoagulant factors 
(Machlus et al, 2009), and therefore the combination of elevated procoagulants, such as 
FVIII and reduced anticoagulants (such as protein C and protein S) in SCD might be 
expected to result in a net increase in thrombin generation potential. Beta thalassaemia 
syndromes, particularly after splenectomy, represent another haemoglobinopathy that is 
associated with in vivo evidence of coagulation hyperactivation and a clinical risk of 
thrombotic events (Ataga et al, 2007). Tripodi et al (2009) demonstrated that while whole 
blood thrombelastometry end points were suggestive of a hypercoagulable state in β-
thalassaemia, plasma thrombin generation profiles were normal. The authors concluded that 
abnormalities in blood cell number or function – as opposed to plasma proteins – contribute 
to the hypercoagulability in β-thalassaemia. The apparent discrepancy between increased 
plasma TAT levels and reduced ETP in this study may be indicative of a similar situation in 
SCD.
Some of the well-recognized complications of SCT include hyposthenuria, renal papillary 
necrosis, renal medullary carcinoma, splenic infarction at high altitude, glaucoma following 
hyphema of the anterior chamber of the eye, exertional rhabdomyolysis and exercise-related 
sudden death (Tsaras et al, 2009; Hooper et al, 2010; Key & Derebail, 2010). Common to 
all these scenarios is the likelihood that sickling of erythrocytes occurs in a vascular bed that 
may be either continuously or intermittently exposed to conditions that favour sickle 
haemoglobin polymerization, including hypoxia (e.g. in the anterior chamber of the eye or in 
the splenic microvasculature at high altitude), acidosis or hyperosmolarity (e.g. in the renal 
medulla).
We evaluated whether some of the mechanisms believed to contribute to activation of 
coagulation in SS (Ataga & Key, 2007) might also be at play in AS. By analogy to SCD, we 
evaluated whether circulating TF levels are elevated in individuals with SCT. We, and 
others have previously reported that cell-associated TF levels are elevated in patients with 
SCD (Key et al, 1998; Colella et al, 2012; Setty et al, 2012). The present study confirmed 
that finding, but failed to demonstrate any increase in WB-TF in AS subjects (Fig 3A). The 
finding of increased MP-TF activity in SS subjects (Fig 3B) is consistent with our previous 
observation (Key et al, 1998), but may be at odds with the study by van Beers et al (2009). 
These authors also found that erythrocyte and platelet MP numbers were elevated in SCD, 
but reported that thrombin generation was dependent on factor XI, but not factor VII, 
thereby implicating the ‘intrinsic’ coagulation pathway. This discrepant observation 
probably reflects technical differences, most notably the presence of plasma in the assay 
reported by van Beers et al (2009). In this study, we were surprised to find marginal, albeit 
insignificantly elevated levels of MP-TF procoagulant activity in subjects with AS (Fig 3B). 
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However, the absent or modest correlations between WB-TF and MP-TF activities 
(respectively) question whether circulating TF is the dominant mechanism contributing to 
activation of coagulation in vivo. Indeed, the role of circulating MP-TF as a mediator of 
coagulation activation and thrombosis in human disease states has been extensively studied, 
although with mixed conclusions to date (Owens & Mackman, 2011; Geddings & 
Mackman, 2013; Lacroix et al, 2013).
In addition, we evaluated whether a number of pro-inflammatory cytokines are elevated in 
subjects with AS, as is the case in SS (Hoppe, 2014). It is well established that one 
mechanism contributing to the ‘cross talk’ between inflammation and coagulation is 
mediated by certain pro-inflammatory cytokines, such as TNF-α, and IL1 and 6 (Levi & van 
der Poll, 2010; Engelmann & Massberg, 2013; Sparkenbaugh & Pawlinski, 2013). However, 
in this study, we were unable to demonstrate any significant increase in these inflammatory 
markers in AS subjects. Consistent with our results, Tripette et al (2010) found no difference 
in baseline levels of multiple cytokines and soluble adhesion molecules [TNFα, IL6, soluble 
(s) Intercellular Adhesion Molecule 1 (ICAM1), sVCAM1, sP-selectin and sL-selectin] in 
patients with SCT, although differences were observed following a sub-maximal exercise 
protocol.
Several limitations of this study warrant discussion. We did not perform formal age- and 
sex-matching among the three cohorts, which resulted in a greater preponderance of females 
among the control group. Secondly, because this was designed as an exploratory study, the 
relatively small sample size may have limited our ability to draw definitive conclusions 
about the role of any single mechanism in the hyper-activation of coagulation in AS. Indeed, 
by analogy to the complexity of the hypercoagulability in SS, other candidate mechanisms 
may also contribute to the excessive activation of coagulation in subjects with AS. For 
example, we have recently evaluated erythrocyte PS expression in subjects with AS. While 
we have not observed any increase in AS subjects compared to controls at baseline in 
preliminary studies, we have detected a significant increase in red cell PS expression in AS 
subjects on haemodialysis compared to matched controls. Furthermore, red cell PS 
expression was highly correlated with plasma TAT levels (Brittain et al, 2010). These data 
suggest that a ‘second hit’, which might include extreme hypoxia in the renal medulla or the 
venous valvular pockets in the lower extremity (Sevitt, 1974; Hamer et al, 1981), may be 
required to perturb AS red cells, and thereby promote their ability to contribute to activation 
of coagulation. We are continuing to evaluate this and other possibilities with the ultimate 
goal of identifying biomarkers of thrombotic risk that may be present in sickle 
haemoglobinopathies.
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Calibrated Automated Thrombography© (CAT). CAT assays on platelet poor plasma was 
performed using 1 pmol/l tissue factor and 4 μmol/l phospholipid, supplied by the 
manufacturer. (A) Time to peak thrombin generation. (B) Endogenous thrombin potential 
(area under the curve). Data comparing these parameters are shown for control (AA), sickle 
cell trait (AS) and sickle cell disease (SS) subjects.
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Fibrin formation. Fibrin formation in platelet poor plasma was measured using a 
turbidimetric assay as described in Methods. Data shown are for onset time for clot 
formation for control (AA), sickle cell trait (AS) and sickle cell disease (SS) subjects.
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Measurement of circulating tissue factor activity. (A) Whole blood tissue factor (WBTF) 
activity was measured as described in Methods, and the concentration expressed as pmol/l. 
This assay is sensitive to all membrane-bound tissue factor in blood. (B) Microparticle tissue 
factor (MPTF) activity was measured on platelet-free plasma, as described in Methods, and 
the concentration expressed as fmol/l. Both figures show the data for control (AA), sickle 
cell trait (AS) and sickle cell disease (SS) subjects.
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